Absence of an adipogenic effect of rosiglitazone on mature 3T3-L1 adipocytes: increase of lipid catabolism and reduction of adipokine expression
Open Access
- 24 January 2007
- journal article
- research article
- Published by Springer Nature in Diabetologia
- Vol. 50 (3) , 654-665
- https://doi.org/10.1007/s00125-006-0565-0
Abstract
The thiazolidinedione (TZD) rosiglitazone is a peroxisome proliferator-activated receptor-γ agonist that induces adipocyte differentiation and, hence, lipid accumulation. This is in apparent contrast to the long-term glucose-lowering, insulin-sensitising effect of rosiglitazone. We tested whether the action of rosiglitazone involves specific effects on mature adipocytes, which are different from those on preadipocytes.Keywords
This publication has 53 references indexed in Scilit:
- Increased plasma adiponectin in response to pioglitazone does not result from increased gene expressionAmerican Journal of Physiology-Endocrinology and Metabolism, 2006
- The effect of PPARγ ligands on the adipose tissue in insulin resistanceProstaglandins, Leukotrienes & Essential Fatty Acids, 2005
- Multiple expression control mechanisms of peroxisome proliferator-activated receptors and their target genesThe Journal of Steroid Biochemistry and Molecular Biology, 2005
- A combination of protein profiling and isotopomer analysis using matrix‐assisted laser desorption/ionization‐time of flight mass spectrometry reveals an active metabolism of the extracellular matrix of 3T3‐L1 adipocytesProteomics, 2004
- Proteomic Analysis of Proteins Associated with Lipid Droplets of Basal and Lipolytically Stimulated 3T3-L1 AdipocytesJournal of Biological Chemistry, 2004
- Rosiglitazone upregulates caveolin-1 expression in THP-1 cells through a PPAR-dependent mechanismJournal of Lipid Research, 2004
- 1,1-Bis(3′-indolyl)-1-( p -substitutedphenyl)methanes Induce Peroxisome Proliferator-Activated Receptor γ-Mediated Growth Inhibition, Transactivation, and Differentiation Markers in Colon Cancer CellsCancer Research, 2004
- PPARgamma agonists in the treatment of type II diabetes: is increased fatness commensurate with long-term efficacy?International Journal of Obesity, 2003
- Peroxisome Proliferator-Activated Receptors: Nuclear Control of MetabolismEndocrine Reviews, 1999
- Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats.Journal of Clinical Investigation, 1998